Patrys

Patrys

Patrys (ASX:PAB)

Patrys’s Deoxymab 3E10 antibody, developed at Yale, prevents cancer cells from self-repairing their DNA when it breaks. Patrys has now upgraded this antibody for human use and has generated encouraging in vivo data across a range of cancers.